Literature DB >> 11860361

DNA-binding of drugs used in medicinal therapies.

G Bischoff1, S Hoffmann.   

Abstract

The interactions of various low-molecular weight substances with DNA are naturally relevant mechanisms in the cellular cycle and so also used in medicinal treatment. Depending on the particular drug structure, DNA-binding modes like groove-binding, intercalating and/or stacking, give rise to supramolecular assemblies of the polynucleotides, as well as influence the DNA-protein binding. In this review, we compare the underlying molecular structures, including general aspects of DNA sequences, with the benefit in medicinal treatment. While so far interest in this field had mainly been devoted to isolated nucleic acid/drug interactions, the present paper will focus on drug efficiencies generating and influencing supramolecular organizations and their complex sequence-dependent structure-activity codes. In particular, the attention will be directed to stereoelectronic relationships. Spatial enantioselective properties are discussed in details. As examples, the drug self-assemblies, as well as the influence of drugs on supramolecular DNA formations are described. A hypothetical connection between drug-influenced DNA-toroids and the formation of micronuclei in tissues will be interpreted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11860361     DOI: 10.2174/0929867023371085

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  15 in total

1.  Epigenetic changes induced by curcumin and other natural compounds.

Authors:  Simone Reuter; Subash C Gupta; Byoungduck Park; Ajay Goel; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

2.  Structural and energetic insights into sequence-specific interaction in DNA-drug recognition: development of affinity predictor and analysis of binding selectivity.

Authors:  Jingheng Ning; Weiwei Chen; Jiaojiao Li; Zaixi Peng; Jianhui Wang; Zhong Ni
Journal:  J Mol Model       Date:  2012-12-29       Impact factor: 1.810

3.  Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin.

Authors:  Jana Staničová; Valéria Verebová; Jiří Beneš
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 4.  Tandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeutics.

Authors:  Catherine Silvestri; Jennifer S Brodbelt
Journal:  Mass Spectrom Rev       Date:  2012-11-13       Impact factor: 10.946

5.  Comparison of the binding stoichiometries of positively charged DNA-binding drugs using positive and negative ion electrospray ionization mass spectrometry.

Authors:  Rajesh Gupta; Jennifer L Beck; Stephen F Ralph; Margaret M Sheil; Janice R Aldrich-Wright
Journal:  J Am Soc Mass Spectrom       Date:  2004-10       Impact factor: 3.109

6.  Comparison of MS/MS methods for characterization of DNA/cisplatin adducts.

Authors:  Zhe Xu; Jared B Shaw; Jennifer S Brodbelt
Journal:  J Am Soc Mass Spectrom       Date:  2012-12-20       Impact factor: 3.109

7.  The role of encapsulation by β-cyclodextrin in the interaction of raloxifene with macromolecular targets: a study by spectroscopy and molecular modeling.

Authors:  Y Sameena; N Sudha; S Chandrasekaran; Israel V M V Enoch
Journal:  J Biol Phys       Date:  2014-07-30       Impact factor: 1.365

8.  Molecular flexibility in ab initio drug docking to DNA: binding-site and binding-mode transitions in all-atom Monte Carlo simulations.

Authors:  Remo Rohs; Itai Bloch; Heinz Sklenar; Zippora Shakked
Journal:  Nucleic Acids Res       Date:  2005-12-13       Impact factor: 16.971

9.  Indirect readout in drug-DNA recognition: role of sequence-dependent DNA conformation.

Authors:  Marcos J Araúzo-Bravo; Akinori Sarai
Journal:  Nucleic Acids Res       Date:  2007-11-26       Impact factor: 16.971

10.  DNA-metallodrugs interactions signaled by electrochemical biosensors: an overview.

Authors:  Mauro Ravera; Graziana Bagni; Marco Mascini; Domenico Osella
Journal:  Bioinorg Chem Appl       Date:  2007       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.